The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

Summary

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• COPD (Chronic Obstructive Pulmonary Disease)

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

40 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Sanofi

Last updated on ClinicalTrials.gov

October 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites